Compare VanEck Gold Miners ETF (GDX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs GSK plc — how do they compare? VanEck Gold Miners ETF trades at $89.29 (market cap $25.65B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.6× VanEck Gold Miners ETF's market cap, and GSK plc pays a 3.9% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and GSK plc for 93 Days on average.
| GDX | GSK | |
|---|---|---|
Market Cap | $25.65B | $91.88B |
Volume | 16,534,046 | 7,730,529 |
52-Week High | $115.84 | $61.18 |
52-Week Low | $68.28 | $43.24 |
Typical Hold Time | 76 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $89.28, up 4.47% over 24 hours but remains in a bearish technical trend with key resistance at $89. The fund provides exposure to gold mining equities, though specific financial ratios are not available in the provided data. Recent news highlights institutional selling and comparisons between gold miners and physical gold investments.
The outlook for GDX is mixed, with technical indicators signaling caution but potential for gains if gold prices rise. Risks include sensitivity to gold prices, interest rate changes, and miner operational issues. Opportunities exist if macroeconomic factors boost gold demand, but volatility is a key concern for investors.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
